vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Liberty Broadband Corp（LBRDA）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.7倍（$261.0M vs $152.6M），Liberty Broadband Corp净利率更高（146.7% vs 34.5%，领先112.2%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 6.1%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $37.0M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 4.3%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
CPRX vs LBRDA — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $261.0M |
| 净利润 | $52.7M | $383.0M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 15.7% |
| 净利率 | 34.5% | 146.7% |
| 营收同比 | 7.6% | 6.1% |
| 净利润同比 | -5.8% | 96.4% |
| 每股收益（稀释后） | $0.40 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | — | ||
| Q3 25 | $148.4M | — | ||
| Q2 25 | $146.6M | $261.0M | ||
| Q1 25 | $141.4M | $266.0M | ||
| Q4 24 | $141.8M | $263.0M | ||
| Q3 24 | $128.7M | $262.0M | ||
| Q2 24 | $122.7M | $246.0M | ||
| Q1 24 | $98.5M | $245.0M |
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | — | ||
| Q2 25 | $52.1M | $383.0M | ||
| Q1 25 | $56.7M | $268.0M | ||
| Q4 24 | $55.9M | $291.0M | ||
| Q3 24 | $43.9M | $142.0M | ||
| Q2 24 | $40.8M | $195.0M | ||
| Q1 24 | $23.3M | $241.0M |
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
| Q4 25 | 40.5% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 45.2% | 15.7% | ||
| Q1 25 | 44.8% | 16.2% | ||
| Q4 24 | 44.3% | 4.9% | ||
| Q3 24 | 39.6% | 11.5% | ||
| Q2 24 | 44.2% | 8.5% | ||
| Q1 24 | 27.5% | 11.4% |
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | — | ||
| Q2 25 | 35.6% | 146.7% | ||
| Q1 25 | 40.1% | 100.8% | ||
| Q4 24 | 39.4% | 110.6% | ||
| Q3 24 | 34.1% | 54.2% | ||
| Q2 24 | 33.2% | 79.3% | ||
| Q1 24 | 23.6% | 98.4% |
| Q4 25 | $0.40 | — | ||
| Q3 25 | $0.42 | — | ||
| Q2 25 | $0.41 | $2.68 | ||
| Q1 25 | $0.45 | $1.87 | ||
| Q4 24 | $0.44 | $2.04 | ||
| Q3 24 | $0.35 | $0.99 | ||
| Q2 24 | $0.33 | $1.36 | ||
| Q1 24 | $0.19 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $180.0M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $954.3M | $10.4B |
| 总资产 | $1.1B | $16.6B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | — | ||
| Q3 25 | $689.9M | — | ||
| Q2 25 | $652.8M | $180.0M | ||
| Q1 25 | $580.7M | $226.0M | ||
| Q4 24 | $517.6M | $163.0M | ||
| Q3 24 | $442.3M | $168.0M | ||
| Q2 24 | $375.7M | $73.0M | ||
| Q1 24 | $310.4M | $108.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | — | $3.6B |
| Q4 25 | $954.3M | — | ||
| Q3 25 | $920.2M | — | ||
| Q2 25 | $856.0M | $10.4B | ||
| Q1 25 | $794.3M | $10.1B | ||
| Q4 24 | $727.6M | $9.8B | ||
| Q3 24 | $660.9M | $9.5B | ||
| Q2 24 | $608.7M | $9.3B | ||
| Q1 24 | $561.4M | $9.1B |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $971.9M | $16.6B | ||
| Q1 25 | $908.9M | $17.0B | ||
| Q4 24 | $851.4M | $16.7B | ||
| Q3 24 | $772.0M | $16.3B | ||
| Q2 24 | $706.4M | $16.0B | ||
| Q1 24 | $646.7M | $15.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | — | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $91.0M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $37.0M |
| 自由现金流率自由现金流/营收 | 29.4% | 14.2% |
| 资本支出强度资本支出/营收 | 0.0% | 20.7% |
| 现金转化率经营现金流/净利润 | 0.85× | 0.24× |
| 过去12个月自由现金流最近4个季度 | — | $-49.0M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | — | ||
| Q3 25 | $32.4M | — | ||
| Q2 25 | $71.3M | $91.0M | ||
| Q1 25 | $60.0M | $78.0M | ||
| Q4 24 | $70.9M | $1.0M | ||
| Q3 24 | $72.9M | $24.0M | ||
| Q2 24 | $64.1M | $27.0M | ||
| Q1 24 | $31.9M | $52.0M |
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | $37.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | $70.8M | $-63.0M | ||
| Q3 24 | $72.6M | $-36.0M | ||
| Q2 24 | $64.1M | $-35.0M | ||
| Q1 24 | $31.7M | $-9.0M |
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | 14.2% | ||
| Q1 25 | — | 4.9% | ||
| Q4 24 | 49.9% | -24.0% | ||
| Q3 24 | 56.4% | -13.7% | ||
| Q2 24 | 52.3% | -14.2% | ||
| Q1 24 | 32.2% | -3.7% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 20.7% | ||
| Q1 25 | 0.0% | 24.4% | ||
| Q4 24 | 0.1% | 24.3% | ||
| Q3 24 | 0.2% | 22.9% | ||
| Q2 24 | 0.0% | 25.2% | ||
| Q1 24 | 0.2% | 24.9% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | 0.24× | ||
| Q1 25 | 1.06× | 0.29× | ||
| Q4 24 | 1.27× | 0.00× | ||
| Q3 24 | 1.66× | 0.17× | ||
| Q2 24 | 1.57× | 0.14× | ||
| Q1 24 | 1.37× | 0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
LBRDA
暂无分部数据
